Загрузка...
The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients
BACKGROUND: Immune checkpoints inhibitors (ICIs) have emerged as a treatment option for several malignancies. Nivolumab, pembrolizumab, nivolumab plus ipilimumab, and atezolizumab plus bevacizumab have been approved for the management of advanced‐stage hepatocellular carcinoma (HCC). We aimed to sys...
Сохранить в:
| Опубликовано в: : | Oncologist |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley & Sons, Inc.
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8176986/ https://ncbi.nlm.nih.gov/pubmed/33314549 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13638 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|